Lupin, drug maker is planning to reproduce its Japanese business model of expansion through acquisitions in markets like Latin America, Europe and Canada. In the next two years company is aiming over $300 million business from the Japanese market on the back of its recent acquisition of I’rom Pharmaceuticals and existing business.
Currently, company has a tie up with state-run Farmanguinhos in Brazil for marketing its products, while in Argentina it has arrangements with third parties to distribute WHO-approved TB drugs. The company already has its subsidiaries in countries like Germany and UK, Lupin.
Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |